triglyceride synthesis

By Targets:	Acyltransferase (1) Fatty Acid Synthase (FASN) (1) LXR (1) MicroRNA (1)
By Research Areas:	Metabolic Disease (7)

Targets Recommended: DNA/RNA Synthesis Microsomal Triglyceride Transfer Protein (MTP) ATGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110381

JNJ-DGAT2-A	Acyltransferase	Metabolic Disease
JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Fatty Acid Synthase (FASN) MicroRNA	Metabolic Disease
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-153497

Vupanorsen IONIS ANGPT-L3Rx; ISIS 703802	Others	Metabolic Disease
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

HY-N9535

tert-OMe-byakangelicin	Others	Metabolic Disease
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells .

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium	Others	Metabolic Disease
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-129098

DMHCA 1 Publications Verification	LXR	Metabolic Disease
DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes .

HY-163452

Squalene synthase-IN-2	Others	Metabolic Disease
Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC₅₀ values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .

Cat. No.	Product Name

HY-L182

Fatty Acids Compound Library	296 compounds
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Fatty Acids Compound Library

296 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Structural Classification Natural Products Classification of Application Fields Dioscorea nipponica Makino Source classification Metabolic Disease Plants Disease Research Fields Dioscoreaceae	Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-N9535

tert-OMe-byakangelicin	Classification of Application Fields Source classification Coumarins Metabolic Disease Phenylpropanoids Plants Umbelliferae Helogyne apaloidea Nutt. Disease Research Fields	Others
tert-OMe-byakangelicin is a coumarin that can enhances the adrenaline-induced lipolytic effect and inhibits insulin-stimulated triglyceride synthesis from glucose in fat cells .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

triglyceride synthesis

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Natural
Products